Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Asensus Surgical FY23 Unaudited Revenue Is Expected To Be Approximately $8.2M-$8.8M Versus Consensus Of $7.79M And Q4 Sales Of $5.1M-$5.7M Versus Consensus Of $4.67M

Author: Benzinga Newsdesk | January 08, 2024 07:52am

2023 Full Year Highlights

Over 3,550 procedures were performed globally, representing 14% growth compared to 2022
In 2023, eight Senhance Surgical Programs were initiated, which is in line with guidance of 8-10 systems
The Company had unaudited cash, cash equivalents and short-term investments, excluding restricted cash of approximately $21.0 million on December 31, 2023
Fourth Quarter Highlights
Over 835 procedures were performed globally using the Senhance® Surgical System
Five Senhance Surgical Programs were initiated, including one in Germany, one in Romania, two in the CIS region and one in Japan at Nagoya University Hospital

Posted In: ASXC